Fluoptics has developed a new technology combining fluorescent tracers and near-infrared imaging that should allow cancer surgeons to see where a tumor ends and healthy tissue begins to within 300 microns. That means improved accuracy for some 5 million cancer operations worldwide every year.
Minatec Video Mini Player
.jpg)
Currently, an experienced surgeon’s eye can only distinguish the difference between healthy and cancerous cells to within one millimeter. The dangers, of course, are injuring healthy organs or leaving cancerous tissue behind during surgery.
Fluoptics technology is already used in research settings, where it aids in deepening our understanding of pathological mechanisms and developing new treatments. It will ultimately be used in clinical settings, where its accuracy, low cost, and radioactive-agent-free use should make it widespread.
Fluoptics uses patents owned by Léti-MINATEC and joint ISERM-CNRS-Grenoble University (UJF).
.gif){kind=logo}
The company was founded in 2009 by a team combining scientific, entrepreneurial, and business know-how and today continues to work with the patent owners under R&D contracts. Fluoptics has five employees.
Find out more at: www.fluoptics.com
